Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (234) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Corporate presentations (26) Apply Corporate presentations filter
- Pipeline (26) Apply Pipeline filter
- Shareholder meeting (24) Apply Shareholder meeting filter
- Team member (21) Apply Team member filter
- Videos (16) Apply Videos filter
- Analyst (12) Apply Analyst filter
- Financial reports (12) Apply Financial reports filter
- Webcasts and audio (12) Apply Webcasts and audio filter
- Investor contact (6) Apply Investor contact filter
- Event (3) Apply Event filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
Interim results for the six months ended 30 June 2021
Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse
Boehringer Ingelheim Exercises Option
Oxford Biomedica Signs Licence & Supply Agreement with Arcellx, Inc. for LentiVector® Platform for CAR-T Therapeutics
Oxford, UK – 13 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy
Oxford Biomedica updates and extends Commercial Supply Agreement for Manufacture of Lentiviral Vectors
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse
Oxford Biomedica Appoints Catherine Moukheibir as Non-Executive Director
Oxford, UK – 14 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy
John Dawson awarded CBE in the Queen's New Year Honours List
Oxford, UK – 31 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy
Oxford Biomedica Signs Licence and Supply Agreement with Cabaletta Bio for LentiVector® Platform
Oxford, UK – 5 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy g